P1065: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ANTI–PD-1–NAIVE RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA

• Nathalie Johnson,
• David Lavie,
• Peter Borchmann,
• Gareth Gregory,
• Alex F. Herrera,
• Leonard Minuk,
• Vladan Vucinic,
• Philippe Armand,
• Abraham Avigdor,
• Robin Gasiorowski,
• Yair Herishanu,
• Colm Keane,
• John Kuruvilla,
• Rachel Marceau West,
• Pallavi Pillai,
• Patricia Marinello,
• John Timmerman

Affiliations

Nathalie Johnson

1 Jewish General Hospital, Montréal, Canada

David Lavie

2 Hadassah Medical Center, Jerusalem, Israel

Peter Borchmann

3 University Hospital Cologne, Cologne, Germany

Gareth Gregory

4 School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia

Alex F. Herrera

5 City of Hope, Duarte, United States

Leonard Minuk

6 CancerCare Manitoba and University of Manitoba, Winnipeg, United States

Vladan Vucinic

7 Leipzig University Medical Center, Clinic and Policlinic for Hematology, Cell Therapy and Hemostaseology, Leipzig, Germany

Philippe Armand

8 Dana-Farber Cancer Institute, Boston, United States

Abraham Avigdor

9 Chaim Sheba Medical Center, Ramat Gan, Israel

Robin Gasiorowski

10 Concord Hospital, University of Sydney, Concord, Australia

Yair Herishanu

11 Sourasky Medical Center, Tel Aviv-Yafo, Israel

Colm Keane

12 Princess Alexandra Hospital, Brisbane, Australia

John Kuruvilla

13 Princess Margaret Cancer Centre, Toronto, Canada

Rachel Marceau West

14 Merck & Co Inc, Rahway, United States

Pallavi Pillai

14 Merck & Co Inc, Rahway, United States

Patricia Marinello

14 Merck & Co Inc, Rahway, United States

John Timmerman

15 UCLA Medical Center, Los Angeles, United States